Abstract
The feasibility of gene therapy for sickle cell anemia (SCA) represents a curative treatment alternative for patients who are candidates for hematopoietic cell transplantation (HCT) but do not have an HLA-matched donor. This therapeutic modality is based on the genetic editing of autologous hematopoietic stem cells and progenitor cells. The main strategies employed include the addition of…